• AIFA registered charity
  • 250K HP 2017
  • All about Allergens
  • AAP Epi update 2017
ASCIA News

  • Shortage of venom immunotherapy products: honey bee, paper wasp and yellow jacket - Supply update from Stallergenes Greer
    13 April 2018:  As communicated in March 2018, events overseas have impacted the ability of Stallergenes Greer to supply venom immunotherapy products to Australia and New Zealand.  The first direct shipment of venom products from JHS to Australia has now arrived, and ASCIA has received th...
  • Novalac Allergy infant formula is back in supply
    27 March 2018:  Bayer Australia Ltd (Bayer), has advised ASCIA that the infant formula Novalac Allergy is back in supply and now being delivered to wholesalers for distribution to pharmacies. Over the next ten working days this stock will be added to supply already in pharmacies acr...
  • Temporary shortage of Stallergenes Greer allergen immunotherapy products
    22 March 2018:  Stallergenes Greer has notified ASCIA of a temporary shortage in the supply of the subcutaneous (SCIT) injectable allergen immunotherapy products. The supply of Stallergenes Greer sublingual allergen immunotherapy (SLIT) products is not impacted.  Despite this temporary su...
  • New stock of EpiPen® 300mcg adrenaline (epinephrine) autoinjectors
    5 March 2018:  Mylan has confirmed that new stock of EpiPen® 300mcg adrenaline autoinjectors arrived last week and will be available in pharmacies this week. This will be followed by further new stock arriving soon.  Please note that stock levels will take some time to return to norm...
  • Shortage of venom immunotherapy products: honey bee, paper wasp and yellow jacket
    2 March 2018:  Stallergenes Greer has recently received information affecting supply of all venom immunotherapy products to Australia and New Zealand, including Honey Bee venom, Paper Wasp venom and Yellow Jacket venom.  This change in circumstances is due to news about a shutdown of ALK ...
  • February 28 is Rare Disease Day
    28 February 2018:  In 2018 the theme for Rare Disease Day is research. Research brings hope to the millions of people living with a rare disease across the world and their families.  It is critically important to identify treatments and cures. A rare disease is defined as one that af...
  • Further Update - EpiPen® 300mcg adrenaline (epinephrine) autoinjectors supply delay
    23 February 2018:   Mylan has advised that new stock of EpiPen® 300mcg adrenaline autoinjectors is now due to arrive by Friday 2 March and is expected to be available in pharmacies the following week. This will be followed by further new stock arriving soon afterwards. This has been updat...
  • ASCIA anaphylaxis e-training for early childhood education/care - ACECQA approved
    13 February 2018:  The Australian Children's Education and Care Quality Authority (ACECQA) has assessed and reapproved ASCIA anaphylaxis e-training for early childhood education/care on 7 February 2018, up until the end of February 2021. The course was previously known as 'ASCIA anaphylaxis e-...
  • Update - EpiPen® 300mcg adrenaline (epinephrine) autoinjectors supply
    February 9, 2018:  Mylan has advised that normal stock of EpiPen® 300mcg adrenaline autoinjectors is expected to be available in pharmacies by late February 2018. A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may nee...
  • AIFA’s 2018 grant round opens 15 January
    January 10, 2018:  Submissions for AIFA's 2018 grant round open on 15 January and close on 6 April 2018.  Please note that the closing date has been extended - it was previously 15 March 2018. AIFA supports innovative early stage projects, encourages collaborative research, prioritises e...
  • ASCIA Highlights 2017 and Priorities for 2018
    December 21, 2017:  As we approach the holiday season we would like to take this opportunity to thank ASCIA members, staff and supporters.  Your significant and generous contributions over the past year are greatly appreciated. ASCIA has achieved so much in 2017, as summarised in the “AS...
  • Allergic rhinitis (hay fever) treatment update
    November 30, 2017:  New Clinical Guidelines from the US on allergic rhinitis (hay fever) treatment were published this week (28 November 2017) in the Annals of Internal Medicine http://annals.org/aim The Guidelines were developed by representatives of the American Academy of Allergy, Asthma a...
  • ASCIA website updates: Chlorhexidine allergy (new) and Anaphylaxis guidelines (updated)
    November 28, 2017:  The following 2 ASCIA documents are now available on the ASCIA website - new ASCIA-ANZAAG Chlorhexidine allergy information and updated ASCIA Guidelines for acute management of anaphylaxis for health professionals. New ASCIA-ANZAAG Chlorhexidine (antiseptic agent) allergy ...
  • EpiPen® Jr and EpiPen® supply update
    November 23, 2017:  Mylan has advised that both EpiPen 300mcg and EpiPen Jr 150mcg adrenaline (epinephrine) autoinjectors have now been shipped to Australian pharmacy wholesalers and stock will become available to pharmacies shortly. The supply of no-charge EpiPen® Jr 150mcg, expiring 30 Novem...
ASCIA is a WAO member society

ASCIA is a WAO member society
Follow ASCIA

ASCIA on facebookASCIA on TwitterASCIA on YouTube

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditation

healthdirect
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health
 information.

Verify here.